Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIT with Recombinant Bet v1 in Birch Pollen Allergy
NCT00410930Phase 2Terminated
- Sponsor
- Stallergenes Greer
- Start
- Nov 2002
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant Bet v 1 in birch pollen allergy, sponsored by Stallergenes Greer. Started Nov 2002; status: terminated.
02
Drugs
recombinant Bet v 1
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT00410930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410930.